Giacomo Boffa1, Nicolò Bruschi1, Maria Cellerino1, Caterina Lapucci1, Giovanni Novi1, Elvira Sbragia1, Elisabetta Capello2, Antonio Uccelli1,2, Matilde Inglese3,4. 1. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy. 2. Ospedale Policlinico San Martino IRCCS, Largo Daneo 3, 16100, Genoa, Italy. 3. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy. m.inglese@unige.it. 4. Ospedale Policlinico San Martino IRCCS, Largo Daneo 3, 16100, Genoa, Italy. m.inglese@unige.it.
Abstract
BACKGROUND: The association between treatment-related lymphopenia in multiple sclerosis, drug efficacy and the risk of infections is not yet fully understood. OBJECTIVE: The objective of this study was to assess whether lymphopenia is associated with short-term treatment response and infection rate in a real-life multiple sclerosis population treated with fingolimod and dimethyl-fumarate. We assessed the associations between baseline absolute lymphocyte count and the lymphocyte mean percentage decrease at 6 and 12 months with treatment response and the occurrence of adverse events over 12 months in the entire cohort of patients and in the two treatment groups separately. METHODS: This is a retrospective observational real-world study of patients with multiple sclerosis treated with fingolimod and dimethyl-fumarate at the MS Center of the University of Genoa between 2011 and 2018. Patients with at least 12 months of follow-up were eligible if [1] they had an Expanded Disability Status Scale assessment at baseline and 12 months after treatment onset, [2] they had undergone brain magnetic resonance imaging at baseline and after 12 months, and [3] absolute lymphocyte counts were available at baseline, 6 and 12 months. Patients shifting from dimethyl-fumarate to fingolimod or vice versa were excluded from the analysis. RESULTS: In total, 137 and 75 patients treated with fingolimod and dimethyl-fumarate, respectively, were included in the analysis. At 12 months, fingolimod-treated patients were more likely to experience grade II and grade III lymphopenia compared with dimethyl-fumarate patients (p < 0.001, χ2 = 94) and had a higher lymphocyte mean percentage decrease (p < 0.001, U = 540). A higher number of previous therapies and a lower baseline absolute lymphocyte count were predictors of lymphopenia at 6 months (p = 0.047, odds ratio = 1.60 and p = 0.014, odds ratio = 1.1) and 12 months (p = 0.003, odds ratio = 1.97 and p = 0.023, odds ratio = 1.1). In fingolimod-treated patients only, female sex and a higher Expanded Disability Status Scale score were predictors of lymphopenia at 12 months (p = 0.006, odds ratio = 7.58 and p = 0.03, odds ratio = 1.56). Neither absolute lymphocyte count at 6 and 12 months nor the mean percentage decrease at 6 and 12 months predicted No Evidence of Disease Activity (NEDA-3) status at 1 year, the occurrence of relapses, disease activity on MRI or disability progression. CONCLUSIONS: Our findings suggest that peripheral blood lymphocyte changes are not associated with short-term treatment response and with the rate of infections during fingolimod and dimethyl-fumarate treatment in real-world patients. Higher treatment exposure and a lower baseline absolute lymphocyte count are risk factors for lymphopenia development during fingolimod and dimethyl-fumarate therapy.
BACKGROUND: The association between treatment-related lymphopenia in multiple sclerosis, drug efficacy and the risk of infections is not yet fully understood. OBJECTIVE: The objective of this study was to assess whether lymphopenia is associated with short-term treatment response and infection rate in a real-life multiple sclerosis population treated with fingolimod and dimethyl-fumarate. We assessed the associations between baseline absolute lymphocyte count and the lymphocyte mean percentage decrease at 6 and 12 months with treatment response and the occurrence of adverse events over 12 months in the entire cohort of patients and in the two treatment groups separately. METHODS: This is a retrospective observational real-world study of patients with multiple sclerosis treated with fingolimod and dimethyl-fumarate at the MS Center of the University of Genoa between 2011 and 2018. Patients with at least 12 months of follow-up were eligible if [1] they had an Expanded Disability Status Scale assessment at baseline and 12 months after treatment onset, [2] they had undergone brain magnetic resonance imaging at baseline and after 12 months, and [3] absolute lymphocyte counts were available at baseline, 6 and 12 months. Patients shifting from dimethyl-fumarate to fingolimod or vice versa were excluded from the analysis. RESULTS: In total, 137 and 75 patients treated with fingolimod and dimethyl-fumarate, respectively, were included in the analysis. At 12 months, fingolimod-treated patients were more likely to experience grade II and grade III lymphopenia compared with dimethyl-fumaratepatients (p < 0.001, χ2 = 94) and had a higher lymphocyte mean percentage decrease (p < 0.001, U = 540). A higher number of previous therapies and a lower baseline absolute lymphocyte count were predictors of lymphopenia at 6 months (p = 0.047, odds ratio = 1.60 and p = 0.014, odds ratio = 1.1) and 12 months (p = 0.003, odds ratio = 1.97 and p = 0.023, odds ratio = 1.1). In fingolimod-treated patients only, female sex and a higher Expanded Disability Status Scale score were predictors of lymphopenia at 12 months (p = 0.006, odds ratio = 7.58 and p = 0.03, odds ratio = 1.56). Neither absolute lymphocyte count at 6 and 12 months nor the mean percentage decrease at 6 and 12 months predicted No Evidence of Disease Activity (NEDA-3) status at 1 year, the occurrence of relapses, disease activity on MRI or disability progression. CONCLUSIONS: Our findings suggest that peripheral blood lymphocyte changes are not associated with short-term treatment response and with the rate of infections during fingolimod and dimethyl-fumarate treatment in real-world patients. Higher treatment exposure and a lower baseline absolute lymphocyte count are risk factors for lymphopenia development during fingolimod and dimethyl-fumarate therapy.
Authors: Clemens Warnke; Thomas Dehmel; Ryan Ramanujam; Carolina Holmen; Nina Nordin; Kathleen Wolfram; Verena I Leussink; Hans-Peter Hartung; Tomas Olsson; Bernd C Kieseier Journal: Neurology Date: 2014-10-31 Impact factor: 9.910
Authors: Yara Dadalti Fragoso; Tim Spelman; Cavit Boz; Raed Alroughani; Alessandra Lugaresi; Steve Vucic; Helmut Butzkueven; Murat Terzi; Eva Havrdova; Dana Horakova; Franco Granella; Javier Olascoaga; José Luis Sánchez-Menoyo; Eugenio Pucci; Michael Barnett; Joseph Bruno B Brooks; Jodi Haartsen Journal: Mult Scler Relat Disord Date: 2017-11-22 Impact factor: 4.339
Authors: Edward J Fox; Fred D Lublin; Jerry S Wolinsky; Jeffrey A Cohen; Ian M Williams; Xiangyi Meng; Marina Ziehn; Scott Kolodny; Bruce A C Cree Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-09-11
Authors: María José Mansilla; Juan Navarro-Barriuso; Silvia Presas-Rodríguez; Aina Teniente-Serra; Bibiana Quirant-Sánchez; Cristina Ramo-Tello; Eva María Martínez-Cáceres Journal: CNS Neurosci Ther Date: 2019-05-07 Impact factor: 5.243
Authors: Robert J Fox; Andrew Chan; Ralf Gold; J Theodore Phillips; Krzysztof Selmaj; Ih Chang; Mark Novas; Jitesh Rana; Jing L Marantz Journal: Neurol Clin Pract Date: 2016-06
Authors: C L Kemmerer; V Pernpeintner; C Ruschil; A Abdelhak; M Scholl; U Ziemann; M Krumbholz; B Hemmer; M C Kowarik Journal: PLoS One Date: 2020-07-27 Impact factor: 3.240
Authors: Rohit Bhatia; M V Padma Srivastava; Dheeraj Khurana; Lekha Pandit; Thomas Mathew; Salil Gupta; M Netravathi; Sruthi S Nair; Gagandeep Singh; Bhim S Singhal Journal: Ann Indian Acad Neurol Date: 2020-04-13 Impact factor: 1.383